Clinical Trial Update: Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC [Phase 2]

View source ↗

Summary

This Phase 2 neoadjuvant trial compares Nab-PH+Pyrrolitinib versus TCbHP in HER2-positive breast cancer and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Nab-PH+Pyrrolitinib
• TCbHP

Snippet

Sponsor: Henan Cancer Hospital | Conditions: Breast Cancer, HER2-positive Breast Cancer | Phase 2 | Status: RECRUITING